Migrating in-lab testing to at-home testing: Setup and procedures

2021 ◽  
Vol 150 (4) ◽  
pp. A300-A300
Author(s):  
Langchen Fan ◽  
Holden D. Sanders ◽  
Morgan S. Eddolls ◽  
Michelle R. Molis ◽  
Lina A. Reiss
Keyword(s):  
2008 ◽  
Vol 139 (2_suppl) ◽  
pp. P83-P84 ◽  
Author(s):  
Jordan C Stern ◽  
Conor Heneghan ◽  
Redmond Shouldice

Objective To test the reliability of the Holter Oximeter for home testing of obstructive sleep apnea. Previous reports have shown a 96% correlation with simultaneous polysomnography and Holter Oximetry in the sleep laboratory. This study was designed to measure reliability of data obtained at home, as well as to obtain information from patients regarding comfort of the device. Methods A prospective study of 120 consecutive patients (ages 5 to 85) presenting to an otolaryngology practice during a 4-month period with complaints of snoring or sleep apnea symptoms. Device: The Holter Oximeter produces an apnea hypopnea index (AHI) based on an automated processing method of a continuous electrocardiogram and pulse oximeter. The reliability of the test was determined by the number of tests completed without interruption due to patient discomfort, electrode or device failure. Results There was 97% data recovery from the home testing device. Data failure was due to faulty memory cards in the device or surface electrode failure. All patients tolerated wearing the device at home, and there were no voluntary interruptions of the tests by patients. On a discomfort scale of 0 to 10 (0: no discomfort and 10: maximal discomfort), the average discomfort score was 2. Conclusions Holter Oximetry represents a new, easy to use, and reliable device for the home diagnosis of obstructive sleep apnea. It can also be used to measure outcomes for the surgical and non-surgical treatment of obstructive sleep apnea in adults and children.


PEDIATRICS ◽  
1976 ◽  
Vol 58 (4) ◽  
pp. 508-512
Author(s):  
Jay Y. Gillenwater ◽  
Charles H. Gleason ◽  
Jacob A. Lohr ◽  
Donald Marion

Bacteriuria screening on 289 children was performed by their parents by means of a self-administered dip-strip culture which was inoculated, incubated, and interpreted in the home. Simultaneous pour-plate quantitative cultures and laboratory-tested dip-strip cultures were done on the same urine specimen which had been tested at home. The dip-strip culture was reliable (89%) in detecting significant bacteriuria with home administration and interpretation. Only 1.6% false-positive results occurred in the home testing. The dip-strip home cultures are an effective way for screening or follow-up of patients with bacteriuria.


2009 ◽  
Vol 24 (4) ◽  
pp. 551-556 ◽  
Author(s):  
Christopher G. Goetz ◽  
Glenn T. Stebbins ◽  
David Wolff ◽  
William DeLeeuw ◽  
Helen Bronte-Stewart ◽  
...  

2021 ◽  
Author(s):  
Ran Liu ◽  
Yuansheng Hu ◽  
Ying He ◽  
Tian Lan ◽  
Jingjing Zhang

Home testing is an attractive emerging strategy to combat COVID-19 pandemic and prevent overloading of the healthcare resources through at-home isolation, screening, and monitoring of symptoms. However, current diagnostic technologies...


2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Caroline Carnevale ◽  
Paul Richards ◽  
Renee Cohall ◽  
Joshua Choe ◽  
Jenna Zitaner ◽  
...  

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Emily J. Ciccone ◽  
Donaldson F. Conserve ◽  
Gaurav Dave ◽  
Christoph P. Hornik ◽  
Marlena L. Kuhn ◽  
...  

Abstract Background The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve as a global health crisis. Although highly effective vaccines have been developed, non-pharmaceutical interventions remain critical to controlling disease transmission. One such intervention—rapid, at-home antigen self-testing—can ease the burden associated with facility-based testing programs and improve testing access in high-risk communities. However, its impact on SARS-CoV-2 community transmission has yet to be definitively evaluated, and the socio-behavioral aspects of testing in underserved populations remain unknown. Methods As part of the Rapid Acceleration of Diagnostics–Underserved Populations (RADx-UP) program funded by the National Institutes of Health, we are implementing a public health intervention titled “Say Yes! COVID Test” (SYCT) involving at-home self-testing using a SARS-CoV-2 rapid antigen assay in North Carolina (Greenville, Pitt County) and Tennessee (Chattanooga City, Hamilton County). The intervention is supported by a multifaceted communication and community engagement strategy to ensure widespread awareness and uptake, particularly in marginalized communities. Participants receive test kits either through online orders or via local community distribution partners. To assess the impact of this intervention on SARS-CoV-2 transmission, we will conduct a non-randomized, ecological study using community-level outcomes. Specifically, we will evaluate trends in SARS-CoV-2 cases and hospitalizations, SARS-CoV-2 viral load in wastewater, and population mobility in each community before, during, and after the SYCT intervention. Individuals who choose to participate in SYCT will also have the option to enroll in an embedded prospective cohort substudy gathering participant-level data to evaluate behavioral determinants of at-home self-testing and socio-behavioral mechanisms of SARS-CoV-2 community transmission. Discussion This is the first large-scale, public health intervention implementing rapid, at-home SARS-CoV-2 self-testing in the United States. The program consists of a novel combination of an at-home testing program, a broad communications and community engagement strategy, an ecological study to assess impact, and a research substudy of the behavioral aspects of testing. The findings from the SYCT project will provide insights into innovative methods to mitigate viral transmission, advance the science of public health communications and community engagement, and evaluate emerging, novel assessments of community transmission of disease.


2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S496-S497
Author(s):  
D Edwards ◽  
M Ibrahim ◽  
R Cooney ◽  
R Boulton

Abstract Background Faecal calprotectin (FC) testing has become a standard non-invasive tool to monitor disease control in Inflammatory Bowel Disease (IBD)(1). Reported patient compliance with submitting samples for hospital testing has been as low as 35% (2). We aimed to evaluate patient compliance with rapid home faecal calprotectin testing kits compared to hospital based testing in our university teaching hospital. Methods 100 patients with a diagnosis of IBD for at least 1 year and attended IBD clinic between January 2019 and August 2020 were selected. Our laboratory ceased performing FC testing in late March and we introduced home testing (BÜHLMANN IBD doc). 50 patients who were, pre-pandemic, requested to bring a stool sample to the laboratory for hospital-based ELISA testing were randomly selected. We compared these to 50 random patients who had a home-based FC testing. Patients who were supplied with home testing kits received training from IBD nurses as well as on-line training materials. Data was collated retrospectively. Compliance was recorded if result was documented within 6 weeks of request. Results Prior to the introduction of home testing, only 52% of the patients’ sampled complied with hospital-based testing. This compared to a 70% compliance rate, when home testing was requested (Figure 1). Figure 1. Comparison of percentage of compliance between hospital and home faecal calprotectin test request. Conclusion The improvement in FC testing compliance with rapid home testing kit compared to laboratory based testing illustrates the benefit of adapting home testing as the standard in future. The considerable increase in compliance by home testing may be due less disruption to patient’s personal life i.e., ability to undergo testing at home, symptoms such as faecal incontinence preventing patients delivering samples to hospital and COVID pandemic compelling patients to stay at home. Adopting rapid FC home testing as standard provides patients with increased locus of control regarding their care, providing health care professionals with rapid results, thus, will improve management of IBD. The ability for patients to perform home test has obvious advantages during the COVID pandemic. References


2021 ◽  
Vol 116 (3) ◽  
pp. e292
Author(s):  
Aaron Lazorwitz ◽  
Elena Rueda Carrasco ◽  
Paulina Cecula ◽  
Jeanelle Sheeder

Sign in / Sign up

Export Citation Format

Share Document